Nonalcoholic Fatty Liver Disease
Conditions
Keywords
Brown Adipose Tissue, BAT Activity, 18F-FDG PET/CT, NAFLD, Plasma Proteomics
Brief summary
This single-center, non-interventional observational study investigated the association between brown adipose tissue (BAT) activity and nonalcoholic fatty liver disease (NAFLD)-related clinical characteristics. Participants who had previously undergone clinically indicated 18F-FDG PET/CT examinations were enrolled. Existing PET/CT imaging data were collected and used to assess BAT activity. Peripheral blood samples were collected for plasma analysis. The study aimed to identify circulating factors associated with BAT activity and to evaluate their relationships with NAFLD-related clinical and metabolic characteristics. No additional PET/CT examination, investigational treatment, or other therapeutic intervention was performed as part of this study.
Detailed description
This was a single-center, non-interventional observational study designed to investigate the relationship between brown adipose tissue (BAT) activity and NAFLD-related clinical and metabolic characteristics. Participants who had already undergone 18F-FDG PET/CT examinations for clinical purposes were recruited. No additional PET/CT examination was performed for this study. Existing PET/CT imaging data were collected and analyzed to assess BAT activity. The maximum standardized uptake value (SUVmax) was used as an imaging parameter to evaluate BAT activity. Peripheral blood samples were collected from participants for plasma analysis. Plasma samples were used to investigate circulating factors associated with BAT activity and their relationships with NAFLD-related clinical and metabolic parameters. This study did not assign any investigational drug, device, behavioral intervention, or additional imaging examination. Only previously acquired PET/CT imaging data, peripheral blood samples, and relevant clinical information were collected and analyzed.
Interventions
None listed
Sponsors
Renmin Hospital of Wuhan University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who had undergone clinically indicated 18F-FDG PET/CT examination. * Willing and able to provide written informed consent and comply with the study procedures. * No long-term use of medications such as glucocorticoids or lipid-lowering drugs; no smoking or excessive alcohol consumption (alcohol intake \<20 g/day). * High BAT activity group: BAT SUVmax ≥2.0, with clear BAT activation in the cervical, shoulder, or supraclavicular regions on PET/CT. * Intermediate BAT activity group: 1.0 ≤ BAT SUVmax \<2.0. * Low BAT activity group: BAT SUVmax \<1.0 or no detectable BAT distribution on PET/CT.
Exclusion criteria
* Use of medications affecting metabolism within the previous 3 months, such as beta-blockers or thyroid hormones. * Contraindications to PET/CT examination, such as claustrophobia or contrast-agent allergy. * Pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Differentially Abundant Plasma Proteins Across BAT Activity Group | At enrollment (single blood collection and assessment of previously acquired PET/CT data) | Participants will be categorized into high, intermediate, and low brown adipose tissue (BAT) activity groups according to BAT SUVmax obtained from previously acquired clinical 18F-FDG PET/CT imaging data. Plasma protein abundance will be measured using label-free quantitative proteomics and expressed as normalized protein abundance. The outcome measure will be the number of plasma proteins meeting the prespecified statistical criteria for differential abundance among the three BAT activity groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Differentially Abundant Plasma Proteins Across BAT Activity Groups | At enrollment | Participants will be categorized into high, intermediate, and low brown adipose tissue (BAT) activity groups according to BAT SUVmax obtained from previously acquired clinical 18F-FDG PET/CT imaging data. Plasma protein abundance will be measured using label-free quantitative proteomics and expressed as normalized protein abundance. The outcome measure will be the number of plasma proteins meeting the prespecified statistical criteria for differential abundance among the three BAT activity groups. |
Countries
China
Outcome results
None listed